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Pulmonary fibrosis corresponds to the end stage ofvarious pulmonary diseases
thatare characterized bythegrowth offibroblasts andthe increase ofcollagen depo-
sition within the alveolar walls (reviewed in references 1-3). Their pathogenesis is
poorly understood and the involvement of fibroblast growth factors, known to be
produced by alveolar macrophages, is suspected (4, 5). TNFalcachectin is one of
the cytokines produced by macrophages activated by inflammatory agents such as
bacterial LPS. TNF has a wide range ofactivities (reviewed in references 6 and 7),
one ofthese being agrowth-promoting activityupon fibroblast celllines (8). In vivo,
we recently foundthat acontinuousinfusion ofTNF within thehypodermis stimu-
lated the growth offibroblasts and led toan increase ofthelocal collagen deposition
(Piguet, P R, G. E. Grau, and P. Vassalli, manuscript submitted for publication).
Bleomycin corresponds to a group ofglycopeptides that are used for the chemo-
therapy of cancer, a therapy that is, however, limited by the occurrence of pulmo-
nary fibrosis. In rodents the administration ofbleomycin has been extensively used
as a model of pulmonary fibrosis (reviewed in reference 2). In the present study,
the role ofTNFin thebleomycin-inducedpneumopathy and fibrosiswasinvestigated.
The evolution of the fibrotic process was found to be associated with an increase
in the level oflung TNF mRNA, suggesting an increase in local TNF production.
Furthermore, injection ofrabbit antiTNF antibody markedly prevented the devel-
opment of pulmonary lesions and fibrosis. These experiments are consistent with
a key role for TNF in at least some types of pulmonary fibrosis.
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Materials and Methods
Mice.
￿
CBAJCaandC57BLt10 (1110) micewerepurchasedfromOLAC Ltd. (Blackthorn,
UK) and bred for two to three generations in our animal facilities.
Bleomycin Administration.
￿
Bleomycin (Lundbeck AVS, Kopenhagen, Denmark) was dis-
solved in HBSSand0.1 U in0.1 mlwasinjected intratracheally. 0.1 Uofbleomycin contained
1 ng of LPS in a limulus amoebocyte lysate assay. The controls were injected with HBSS
only. Continuous intraperitoneal administration wasperformedusinganAlzet osmoticmini-
pump (no. 2002 Alza Corp., Palo Alto, CA) delivering a total dose of2 Uwithin 15 d.
Deletion ofthe CD4* (L3T4*) and CD8* (Lyt-2*) T Lymphocyte Subsets.
￿
Mice were injected
everyother daywith asciticfluid producedby hybridoma H-35-17.2, aratIgG2b anti-CD8,
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or GK 1 .5, a rat IgG2b anti-CD4, as described previously (9). The controls were injected
with HBSS only.
Assayfor TNF.
￿
TNF activity was determined using the lysis of the L929 cell line (10).
LightandElectronMicroscopy.
￿
The lungs were fixed by intracheal instillation offormol sub-
limate and embedded within paraffin. Sections were stained by the hematoxilin-eosin and
Masson trichrome stains. For a semiquantitative evaluation of the extent of lung damage,
sections from the right and left lung of individual mice were projected on a multipurpose
grid with 168 points. The number of points falling on normal or severely damaged tissue
was established. This gave an approximative evaluation of the percentage ofdamaged paren-
chyma. For embedding in epon, the lungs were fixed by intratracheal instillation of 2%
glutaraldehyde in cacodylate buffer (0.1 M, pH 7.2). Sections were prepared from three blocks
from the left lung for each individual mouse and were stained with toluidine blue. For EM,
700-A ultrathin sections were stained with 1% uranyl acetate in 100% methanol and lead
citrate and were examined with an electron microscope(400; Philips Electronic Instruments,
Inc., Mahwah, NJ) at 80 Kv.
Northern Blot Analysis of TNF-a, IL-1-a, and Granulocyte-macrophage CSF(GM-CSF)' mRNAs
in TotalLung RNA. The lungs were washed with saline and frozen in liquid nitrogen. They
were subsequently thawed by mincing in a guanidine-thiocyanate solution and the totallung
RNA was isolated by guanidine-thiocyanate/cesium chloride centrifugation (11). Northern
blotswere performed as described elsewhere (12). Briefly, RNAs denatured with glyoxal were
separated on 1.2% agarose gels (4 jig/lane) and were transferred onto nylon membranes.
Equality of sample loading and efficiency of the transfer were controlled by staining with
methylene blue. Filters were hybridized with 12P-labeled cRNA probes (13). The probes for
TNFa, IL-1-a, and GM-CSF have been described elsewhere (12, 13).
Rabbit Anti-mouse TNFAntibodies.
￿
Mouse rTNFa was a kind gift from B. Allet Glaxo,
IMB, Geneva, Switzerland. Purification of the cytokine and the preparation of rabbit anti-
TNF antibody have been described previously (14). IgG fraction from antiTNF or normal
serum were deaggregated by ultracentrifugation at 150,000 g for 150 min, and 1 mg was in-
jected intravenously.
Evaluation oftheLung Hydroxyproline Content.
￿
The total lung hydroxyproline concentration
was determined using described methods (15). Briefly, the lungs were submitted to an acid
hydrolysis, the hydrolysate was neutralized, extracted with phenol-chloroform-isoamylalcool,
and the hydroxyproline concentraton was determined colorimetrically (15).
Statistical Evaluation.
￿
Statistical analysis was performed using the nonparametric Mann-
Whitney U test.
Results
Intratracheal Instillation ofBleomycin Increases the TNFmRNA Level in theLung Whereas
Those of Interleukin 1 and GM-CSF Remain Undetectable. Bleomycin administration
did not lead to a detectable increase of the serum TNF activity (not shown). How-
ever, evidence for a local increase of TNF production was provided by the analysis
of the lung TNF mRNA level. RNA from the lungs of individual mice were ex-
tracted and analyzed by Northern blot hybridization at various times after intracheal
instillation of bleomycin (Fig. 1). An increase ofTNF mRNA level was not apparent
2 d after bleomycin instillation (not shown), but was detectable in 12 mice killed
between day 5 and 15 (Fig. 1). In contrast, the mRNAs for IL-1 and GM-CSF were
not detectable after instillation of bleomycin, but evident 1-2 h after LPS injection
(Fig. 2).
Influence ofAntiTNF-ce Antibody upon the Systemic and Pulmonary Effects of Bleomycin
Administration.
￿
1 mg of control or antiTNF IgG was injected on days 1 and 8 after
I Abbreviation used in this paper: GM-CSF, granulocyte-macrophage CSFPIGUET ET AL .
FIGURE 1.
￿
After isolation of the total lungRNA from individual mice, TNFamRNA was de-
tected by Northern blot hybridization (4 tag/lane). (Lanes 1 and 2) Mice killed 5 d after an in-
tratracheal instillation of solvent ; (lanes 3 and 4) 5 d after 0.1 U of bleomycin ; (lanes 5 and 6)
15 d after 0.1 Uofbleomycin; (lanes 7-10) mice instilled with bleomycinand treated with solvent
(lanes 7and 8) or anti-CD4 plus anti-CD8 mAb (lanes 9and 10) and killed on day 5; (lane 11)
mouse killed 90 min after an invravenous injection of2001cg ofEscherichia coliLPS . Arrows indi-
cate the position of the TNFmRNA .
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the intratracheal administration of 0.1 U of bleomycin, and the mice were killed
on day 15 . AntiTNF activity wasdetectable in the serumduring the treatment (14) .
The bleomycin instillation induced some mortality, ranging between 0 and 30% in
different experiments, and this was not significantly affected by the treatment with
antiTNF IgG (not shown) . Study of histological sections suggested that mortality
was related either to extensive lung damage (see below) or to infectious complica-
tions that were occasionally observed in mice receiving antiTNF IgG . Indeed, this
treatment is known to compromise the resistance to some bacteria (16) . Bleomycin
administration also led to a weight loss that was partially prevented by antiTNF
antibody. The body weight of the saline instilled controls were of77% (±12) or 85%
(t 17) for the mice treated with nonimmune or antiTNF IgG, respectively (mean
t SD on day 15 after bleomycin intratracheal instillation, difference not significant
at p > 0.05) .
Study of thelung by lightmicroscopy 15 d after intratracheal instillation ofbleomycin
FIGURE 2 .
￿
Expression of IL-1-a and
GM-CSF mRNA in the whole lung
RNA. (Lanes 1 and 2) Mice instilled
with the solvent ; (lanes 3 and 4) with
bleomycin; (lanes 5and 6) mice killed
30 and90 min after anintravenous in-
jection of200 jig ofE . coli LPS . Arrow
indicates the position oftheGM-CSF
and IL-1 mRNA.658
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FIGURE 3 .
￿
Histologic sections from the left lung ofCBAmice 15 d after an intratracheal instilla-
tion of 0.1 U of bleomycin and treated with antiTNF (A) or control (B) IgG (x40).
showed areas of increase of the cellularity of the alveolar septa associated with a
total disruption of the alveolar architecture (Fig . 3) . Collagen deposition, revealed
with the trichrome stain, was seen in the most severely damaged area . Because of
their heterogeneity in the different lobes, these alterations were difficult to quantify.
Sections from the right and left lungs ofseven mice treated with antiTNF or nonim-
mune IgG were examined . The severely damaged area (i .e ., disruption of the al-
veolae and presence of collagen) represented 45 ( ±25) and 15% (t 12) for the mice
treated with nonimmune and antiTNF IgG, respectively (mean t SD) .
To evaluate more directly the collagen deposition, the total lung hydroxyproline
content was determined . After single intratracheal administration ofbleomycin, the
lung hydroxyproline content was increased by -50% after 15 d. This increase was
nearly completely prevented by injection of antiTNF antibody (Fig . 4) .
Role of T Lymphocytes in the Pneumopathy and the TNF mRNA Accumulation .
￿
Since
athymicnude mice are resistant to thebleomycin-induced pneumopathy (17),Tlym-
phocytes are suspected of being involved . It has been shown previously that treat-
ment in vivo with anti CD4 orCD8mAb results in significant or complete depletion
of the respective T lymphocyte subset (9). The pulmonary fibrosis, measured by
the lung hydroxyproline content, was to some extent attenuated by the deletion of
theCD4 or theCD8 T lymphocyte subset and completely prevented by treatment
FIGURE 4 .
￿
Total lung hydroxyproline ofCBA
mice killed 15 d after an intratracheal instil-
lation of 0.1 U ofbleomycin . In parentheses
are thenumber ofanimals studied. Mice were
injected with nonimmune or antiTNFrabbit
IgG (see Materials and Methods) .PIGUET ET AL .
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FIGURE 5 .
￿
Total lunghydroxyproline ofmice
instilled with bleomycin and treated with
anti-T lymphocyte subset mAb . Mean(tSD)
ofthe values observed with morethan six mice
per group.
with bothmAbs (Fig. 5) . Furthermore, thebleomycin-induced increase ofTNFmRNA
level was prevented by the combined treatment with the anti-CD4 andCD8 mAbs,
when examined on day 5 (Fig. 1) or 15 (not shown) .
Effect ofAnti-TNFAntibody on Pulmonary Lesions Produced by Intraperitoneal Administra-
tion ofBleomycin. Administration ofbleomycinby intraperitoneal injection does not
lead to a rapid fibrosis (18) ; 15 d after acontinuous injection ofatotal dose of 2U of
bleomycin, the increase ofthe lung collagen content, measured by thetotalhydroxy-
proline content, wasN5% above thecontrols receivingthe solventonly (not shown) .
However, an alveolar damage was evident that, in contrast to that induced by intra-
tracheal instillation, was diffuse and therefore easier to quantify. Alveolar oedema
and thickening of the alveolar septa were evident by light microscopy (Fig. 6 B),
while epithelial and endothelial cells damage were evident when examined on the
electron micrographs (Fig. 6D) . These alterationswere attenuated or absent in mice
passively immunized with antiTNF IgG (Fig . 6, A-D) .
Discussion
The administration ofbleomycin in rodents is a model for alveolar damage and
pulmonary fibrosis (2) . The reason for the predominant pulmonary damage after
bleomycin injection is probably related to the fate of the drug, which is found local-
ized within the alveolar epithelium 3-4 d after an intravenous injection (19) . 5 d
after intratracheal injection, an increase of the TNFmRNA level is evident (Fig .
1) . This increase is relatively moderate in comparison with that induced by a lethal
dose of LPS (Fig . 1), but much more sustained since it is detectable during 2 wk
after a single bleomycin injection, compared with only 2-3 h after LPS . This obser-
vation raises the question of whether a local increase of theTNF production plays
some role in the antineoplastic effects of bleomycin.
The bleomycin-induced pneumopathy is not a direct result of a toxicity of the
drug since it involves aT cell-mediated immune response. This is indicated by an
influx ofT lymphocytes within the lung 3-4 d after bleomycin instillation (20) and
by the resistance of the athymic nude mice to bleomycin (17) . In agreement with
those observations, the present experiments provide two additional informations .
First, either theCD4+ or CD8 * T lymphocyte subset alone is capable of inducing
some degree offibrotic response (Fig . . 5), and second, the presence oftheTlympho-
cytes is required for an increase of pulmonary TNFmRNA level (Fig . 1) .
The cellular origin of the pulmonaryTNF has not yet been established andmay
involve more than one cell variety. Macrophages are in quantitative terms the most660
￿
TUMOR NECROSIS FACTOR AND PULMONARY FIBROSIS
FIGURE 6.
￿
Alveolitis produced by an intraperitoneal administration of bleomycin . Mice were
treated with nonimmune (B and D) or antiTNF (A and C) rabbit IgG . (A) The alveola have
anormal appearance, while in B, oedema and thickening of the alveolar septa are evident (tolu-
idine blue, x 125) . Endothelial (small arrow) and epithelial (wide arrow) cell damage are evident
on EM in D, while the alveolar septa are unaltered in C(x 2,800) . Two blocks from three mice
in each group were examined with similar observations .
important producers ofTNF(6, 7), and the involvement ofthealveolarand intersti-
tial population is likely. T lymphocytes can also releaseTNF (21), but the absence
of detectable GM-CSF mRNA (Fig . 2), a cytokine usually produced by activated
T lymphocytes, suggests that their number within the lung and their direct contri-
bution to theTNF production is moderate . It appears more likely that T lympho-
cytes increase, by the secretion ofother cytokines, both the number of macrophages
and their activation to secrete TNF, as appears to be the case in other types of T
cell-induced and TNF-mediated immunopathological reactions (22) .
Thevariouscomponents of bleomycin-inducedpneumopathy (i .e ., alveolardamage,
growth ofinterstitial fibroblasts, deposition of collagen [18, 19, 23]) were influenced
by the administration of antiTNF antibody. This observation has to be related to
the effects ofTNF upon the alveolar walls and the fibrotic process . When delivered
intravenously, TNF induces a diffuse alveolar damage, notablywith necrosis of alve-
olar epithelial and endothelial cells (24, 25) . TNF also exerts a growth-promoting
activity upon fibroblasts, since asubcutaneous continuous infusion leads to a markedPIGUET ET AL.
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increaseoffibroblast proliferation and collagen deposition (Piguet, P F, G. E. Grau,
and P Vassalli, manuscript submitted for publication). Thus, the susceptibility of
the lesions to the antiTNF antibody, as well as the capacity ofTNF to induce alve-
olar damage and fibrosis, strongly suggests that TNF is indeed the effector ofboth
alveolar damage and fibrosis. Avarietyofother cytokineshavebeen showntoinfluence
fibroblasts in vitro, such as platelet-derived growth factor (26), IL-1 (27), andTGF0
(28). A further element ofcomplexity results from the possibility that these medi-
ators mayinduce each other, asithas been demonstrated fortheinductionofplatelet-
derived growth factor and IL-1 by TNF (29). In this context, the striking influence
ofantiTNF antibody upon the collagen deposition might indicate that other medi-
ators are not produced in significant quantities, an interpretation that, in the case
of IL-1, is supported by the absence of detectable IL-1 mRNA (Fig. 2). Alterna-
tively, or in addition, their involvement might be dependent upon THE
In conclusion, the following evidences are in favor of a key role of TNF in the
various components ofthebleomycin-induced pneumopathy: first, TNFcan induce
alveolar damage, fibroblast growth, and collagen deposition; second, a single injec-
tion ofbleomycin induces a sustained increase of the TNF mRNA level within the
lung; andthird, antiTNF antibodyprevents thebleomycin-induced alveolardamage,
growth offibroblasts, and collagen deposition. Recent experiments in our labora-
tory indicate that this conclusion is also valid for pulmonary fibrosis induced by
silica particles.
Summary
The role ofTNFa/cachectin in the pneumopathy elicited by bleomycin hasbeen
investigated. After a single intratracheal bleomycin instillation, an increase of the
lung TNFa mRNA level was evident, from days 5 to 15, as shown by Northern
gelanalysis ofwholelung RNA. In contrast, lung IL-1-a and GM-CSF mRNA were
not detectable. In mice passively immunized with rabbit anti-mouse TNFa IgG,
the bleomycin-induced collagen deposition, evaluated by the totallung hydroxypro-
line assayon day 15, was prevented. Depletion ofthe CD4 and CD8 T lymphocytes
byanin vivotreatmentwith mAb preventedthe bleomycin-induced increase ofTNF
mRNA level and fibrosis. After an administration ofbleomycin in continuous in-
traperitoneal perfusion, the diffuse alveolar damage observed by light and electron
microscopy was almost completely prevented by antiTNF antibody. These results
indicate that in response to bleomycin, the Tlymphocytes induce, by an undefined
mechanism, an increase ofthe pulmonary TNF production, which leads to alveolar
damage, growth of fibroblast, and collagen deposition.
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